- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02252991
Adaptated Physical Activity in Cancerology (APACAN)
APACAN study_Adaptated Physical Activity in Cancerology
This trial will measure the fatigue in breast cancer patients.
Two groups of patients will be realised:
- Arm A: Physical activity during treatment
- Arm B: No physical activity during treatment but after
The aim of the study is to decrease fatigue, with adequate physical activity, in primary breast cancer patients who receive a treatment for their pathology.
Studie Overzicht
Gedetailleerde beschrijving
This is an open monocentric study, randomized in two parallel arms with a waiting list.
The duration of the physical activty will vary according to the duration of the treatment: from 2 to 6 months.
Several questionnaries (fatigue, quality of life, ...) will be given to patients at the inclusion, at the end of the period of treatment and 3 to 6 months after the end of treatment.
One hundred patients are necessary in this study (fifty in each arm). We expect to a stability of the fatigue in Arm A compared to an increase of the fatigue in arm B.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Women aged 18 to 75 years (included)
- Patient with a breast tumor, regardless of the stage and size (except metastatic patients)
- Patient with a local recurrence of breast cancer
- Patient with a second non-metastatic breast cancer
- Breast cancer treated, regardless of the surgery, at least by radiotherapy, chemotherapy (neoadjuvant or adjuvant) +/- targeted therapy
- A mandatory social security affiliation.
- Obtaining informed consent in writing, signed and dated.
- Medical certificate of fitness to practice physical (issued by the medical oncologist)
Exclusion Criteria:
- Cancer other than breast cancer and / or associated with breast cancer
- Metastatic Cancer
- in case of surgery before treatment, delay before beginning treatment inferior to 1 month post-surgery
- Men
- Woman pregnant
- Patient with cognitive or psychiatric disorders
- Patients suffering from disability
- Significant alterations in nutritional status (malnutrition with BMI <19, obese with BMI> 40, BMI)
- Cardiac contraindication to physical activity
- Knowledge and understanding of the French language enough not to learn the correct way of self-administered questionnaires or respond to questioning
- Participation in another clinical study with a similar objective
- Inability to reach the centers where physical activity takes place
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Ander: Arm A with physical activity during the treatment
In the arm A, patients will realise physical activity during the treatment.
Blood samples will be realised.
Questionnaries will be given to the patients.
|
Patients will realise physical activity either during their treatment, either after their treatment.
They will have practise a physical activity three times per week.
|
|
Ander: Arm B with physical activity after the treatment
In the arm B, the physical activity will be realised after treatment.
Blood samples will be realised.
Questionnaries will be given to the patients.
|
Patients will realise physical activity either during their treatment, either after their treatment.
They will have practise a physical activity three times per week.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Difference between the questionnaries scores MFI 20 (specific fatigue) between baseline and end of treatment.
Tijdsspanne: up to 6 months
|
The scores of fatigue at the end of treatment and at the inclusion will be compared.
|
up to 6 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
QLQ-C30
Tijdsspanne: up to 6 months
|
Comparison of the scores of QLQ-C30 assessed at the end of the treatment and at the inclusion.
|
up to 6 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Yves Jean Bignon, MD,PhD, Centre Jean Perrin
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2014-A00091-46
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .